Hims & Hers faces battles as federal regulators and Novo Nordisk move to disrupt its sale of compounded weight loss drugs.

Him stock rose after the telehealth company announced that it had agreed to acquire Eucalyptus in a $1.15 billion deal.

Hims & Hers (HIMS) stock rises after-hours as the company announces a $1.15B deal to acquire Australia's Eucalyptus, expanding into new global markets.

Feb 19 (Reuters) - Hims & Hers Health said on Thursday it will acquire Australian digital health company Eucalyptus in a deal valued at up to $1.15 billion, as the U.S. telehealth platform seeks to ...

The agreement – which has been valued at up to $1.15 billion – is the strongest signal yet of Hims & Hers' aspirations to grow into a global health player, with the addition of Eucalyptus giving it a ...

Hims & Hers Health, Inc. faces volatile earnings as compounded GLP-1 setbacks pressure shares. Click for this HIMS stock ...

Carillon Tower Advisers, an investment management company, released its fourth-quarter 2025 investor letter for the “Carillon ...

Hims & Hers Health shares plunged Monday after the telehealth company said it would stop selling its compounded weight-loss ...

Novo Nordisk, the maker of the weight loss drug Wegovy, is suing Hims & Hers for selling a cheaper version of the drug, the ...

Everyone's ganging up on Hims & Hers stock this week.

Today, Feb. 9, 2026, investors are reevaluating Hims & Hers after it pulled its weight-loss pill, facing legal action and FDA ...